Zevra Therapeutics: Q4 Earnings Insights
Portfolio Pulse from Benzinga Insights
Zevra Therapeutics (NASDAQ:ZVRA) reported Q4 earnings with a -48.0% miss on estimated earnings, posting an EPS of $-0.4 against an estimate of $-0.27. Revenue increased by $10.92 million from the same period last year. Despite missing EPS estimates last quarter, the share price increased by 1.0% the following day.
March 28, 2024 | 9:05 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Zevra Therapeutics reported a significant miss in Q4 earnings with a -48.0% deviation from estimated EPS, but showed a notable increase in revenue compared to the same period last year.
Although Zevra Therapeutics missed the EPS estimate significantly, the increase in revenue and historical resilience of the share price following earnings misses suggest a neutral short-term impact. Investors may weigh the negative earnings surprise against the positive revenue growth and past price resilience.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100